An Overview of Microneedle Mediated Transdermal Drug Delivery: Painless Passage through the Skin Barrier

Topical application is an excellent method of treatment since it does not go through the gastro-intestinal system and first-pass effect, thus causing minimal side effects while targeting the lesions. The skin acts as one of the major biological barriers; the effectiveness of topical application is mainly dependent on the integrity of the stratum corneum since this layer requires permeation before reaching the desired location for bioactivity and disease individualization dosage determination. Therefore, the permeability and personalization of the dosage are critical factors determining the efficacy of this form of therapy.¹

Transdermal drug delivery (TDD) represents a globally recognized alternative to oral and parenteral administration, offering distinct clinical advantages. These include the avoidance of hepatic first-pass metabolism, bypass of gastrointestinal degradation, and a significant reduction in systemic side effects.² TDD systems provide a steady-state delivery profile, which is particularly beneficial for chronic disease management where patient compliance is often a challenge. However, the inherent barrier function of the skin, primarily centered in the stratum corneum, strictly regulates the permeability of exogenous substances. This barrier typically restricts effective permeation to drug molecules with low molecular weight (<500 Da), moderate lipophilicity (log P 1–3) and high potency.³

The limitations of passive diffusion have led to the development of various enhancement strategies, ranging from chemical enhancers and thermal ablation to physical methods such as iontophoresis, electroporation and sonophoresis. While these methods can increase permeability, they are often associated with skin irritation, require complex and expensive equipment, or fail to deliver larger biotherapeutics efficiently.⁴ Microneedles (MNs) offer a superior solution by mechanically creating micro-conduits that are large enough to allow drug transport but small enough to avoid stimulating dermal nociceptors and blood vessels. This "painless" technology has the potential to transform the delivery of vaccines, hormonal therapies, and dermatological treatments. This review synthesizes the current advancements in microneedle design, fabrication, and characterization, providing a comprehensive roadmap for their successful clinical translation.⁵

Transdermal drug delivery is a medical approach to treating diseases affecting the skin and other body systems, especially by circumventing first-pass metabolism. In addition, transdermal drug delivery allows for controlled dosage over an extended period of time. Given the complex physiology of the skin with its vast networks of vascular and lymphatic blood vessels, it acts as a perfect point of entry for systemic drug administration.⁶ Furthermore, the skin serves as a biological reservoir for medications. This is particularly advantageous for drug candidates with short biological half-lives, as it eliminates the need for frequent dosing and maintains stable plasma concentrations. But, the primary evolutionary role of the skin is that of defence, with the stratum corneum (SC) being a strong physical barrier, which impedes the penetration of most drugs into the skin. The main issue in transdermal delivery is, therefore, how to increase the permeability of the stratum corneum barrier.⁷ Three generations of delivery technologies have emerged to address this problem, with the first generation of drug delivery techniques restricted to only small, lipophilic drugs at relatively low doses. In contrast, the second generation involved the use of chemical enhancers and iontophoresis to enable the delivery of a larger variety of drugs. Recently, the latest generation of technologies involving microneedles, thermal ablation, and electroporation has made it possible to deliver large biological drugs such as insulin and parathyroid hormone.⁸

2. PHYSIOLOGY AND BARRIER FUNCTION OF THE SKIN

The skin is the largest organ of the human body, accounting for approximately 15% of total body weight. It serves as a crucial interface, providing protection against UV radiation, chemicals, and pathogens, while also performing roles in thermoregulation and immune surveillance.

2.1. Epidermal Layers and the Stratum Corneum

The epidermis is the superficial, non-vascularized layer, ranging in thickness from 50 µm to 1.5 mm. It is composed primarily of keratinocytes in various differentiation stages. The outermost layer, the stratum corneum (SC), is the most significant barrier to drug diffusion. The SC consists of 15 to 20 layers of non-viable, flattened corneocytes densely packed with keratin filaments.⁹ These cells are surrounded by a continuous lipid matrix composed of ceramides, free fatty acids, and cholesterol. This "brick-and-mortar" structure is remarkably impermeable to most substances, particularly polar and high-molecular-weight molecules.¹⁰

2.2. Dermis and the Vascular Network

The dermis, located beneath the epidermis, is a thicker (0.5 to 3 mm) layer composed of collagen and elastin fibres. It contains blood vessels, lymphatic vessels, hair follicles, sweat glands, and nerve endings. The papillary dermis, adjacent to the epidermis, is rich in capillaries, making it the primary target for systemic drug absorption once the stratum corneum barrier is breached. The deep dermis provides structural support and anchors the skin to the underlying hypodermis.¹¹

2.3. Molecular Transport and the rationale for Microneedles

Drug transport through the skin occurs primarily via passive diffusion, governed by Fick’s First Law: $J = -D (dc/dx) $, where $J$ is the flux and $D$ is the diffusion coefficient. The SC’s low diffusion coefficient is the primary bottleneck for systemic delivery. Microneedles circumvent this by physically removing the SC barrier in localized areas, effectively creating "macro-pores" through which drugs can diffuse at rates several orders of magnitude higher than passive permeation. This mechanical disruption is temporary; the skin’s barrier function typically restores itself within 24 to 72 hours through natural repair mechanisms.¹²

3. MICRONEEDLE DRUG DELIVERY

Transdermal drug delivery has traditionally been based on the duality of topical creams and hypodermic needles. Conventional drug delivery techniques employ metal needles or syringes to administer either subcutaneous or intramuscular injections; however, this method is associated with severe pain and infection caused by blood-borne pathogens. Additionally, most topical creams cannot efficiently deliver medications across the impermeable surface of the skin. To address this problem, microneedle (MN) technology was developed as a combination approach integrating the benefits of physical insertion with those of patches applied directly to the skin.¹³ Microneedles represent an array of tiny needles attached to a patch-like substrate and designed in a way to penetrate the upper layers of the skin without affecting sensitive pain receptors. With an average thickness of 1500 micrometers, the epidermis is easily pierced by microneedles that have a smaller width. Hence, microneedle technology offers painless delivery of medications across the epidermis with minimal chances of adverse effects. Moreover, microneedles provide precise and rate-controlled delivery of medication in comparison with conventional drug delivery methods. These Microneedles can be prepared using Silicon, Polymer, Glass and Metal.¹⁴

The emergence of Microneedle (MN) technology has been recognized as one of the most revolutionary approaches towards transdermal drug delivery, due to their ability to enhance therapeutic potency and efficacy. The absence of any first-pass effect along with the ability to deliver medication without causing stomach irritation, makes Microneedles ideal for the effective delivery of therapeutics. These micron-scale structures, fabricated on a suitable substrate, can deliver therapeutic drugs without causing any irritation and pain since they have the ability to traverse through the outermost layer of the skin without causing any damage. Even though a variety of microneedle types are available in the market, polymers-based systems are the most successful ones in terms of systemic delivery of protein-based medicines.¹⁵ Contrary to microneedles made of metals, ceramics, etc., or those that are coated with therapeutic molecules, polymer-based arrays are more efficient for delivering high doses of therapeutics since solid and coated microneedles cannot carry sufficient amounts of drugs.¹⁶ Microneedles have been revolutionizing the world of medical treatment through their innovative approach of delivering medications to patients. This is achieved through creating temporary, microscopic channels through the stratum corneum in order to overcome the major barrier presented by the skin, thereby facilitating the systemic absorption of various macromolecules as well as pharmacological agents. The pores that are created by microneedles are small enough not to be detected by pain receptors, thus preventing any form of discomfort to patients. At present, there are five main types of microneedle systems identified based on their structure.¹⁷

3.1. Classification of Microneedle Systems

Microneedles are categorized based on their structural design and the method by which they facilitate drug delivery, each offering specific advantages for different therapeutic needs.

Fig.1: Microneedle delivery methods

Fig.2: Types of Microneedle Mechanism

4. FABRICATION STRATEGIES FOR MICRONEEDLE ARRAYS

The fabrication of microneedles requires sub-micron precision to ensure needle sharpness, structural integrity, and consistency across the array. The choice of technique is determined by the material properties and the intended application.

4.1. Micro Moulding and Casting

Micro moulding is the most prevalent technique for producing polymeric and dissolving microneedles. The process begins with the creation of a "master mould" using high-precision techniques like laser machining or photolithography. The polymer solution, containing the therapeutic agent and stabilizers, is dispensed into the PDMS mould. To ensure the viscous solution fills the sharp needle tips, vacuum or centrifugal forces (e.g., 4000 RPM for 10 minutes) are applied. The solvent is evaporated under controlled conditions (e.g., 25°C, 40% RH) for approximately 24 hours. A backing membrane is then added to provide mechanical support. This method is highly scalable and cost-effective for mass production.^28,29

4.2. Photolithography and Etching

Photolithography is the gold standard for fabricating silicon and metal microneedles. The process involves coating a silicon wafer with a light-sensitive photoresist and exposing it to UV light through a mask to define the needle patterns. Deep Reactive Ion Etching (DRIE) is then used to remove material, creating high-aspect-ratio shafts with vertical walls. Tapered needles can be produced using wet chemical etching, which takes advantage of the crystal orientation of the silicon. While these methods provide exceptional dimensional accuracy, the high cost of equipment and the fragility of silicon have led researchers to explore more robust alternatives like stainless steel and polymers.³⁰

4.3. 3D PRINTING AND ADDITIVE MANUFACTURING

Additive manufacturing has emerged as a disruptive force in microneedle fabrication, offering the ability to create complex and customized geometries that are impossible to achieve with traditional moulding.

Stereolithography (SLA): Uses a UV laser to cure photosensitive resin layer-by-layer. SLA can produce MNs with diverse shapes and sizes with a resolution of ~25 µm.

Two-Photon Polymerization (2PP): This technique uses a highly focused femtosecond laser to trigger polymerization only at the focal point. With a resolution of less than 100 nm, 2PP can produce needles with incredibly sharp tips and complex internal architectures, such as porous or barbed shafts.³⁰

Digital Light Processing (DLP): Offers faster printing speeds than SLA by projecting an entire layer of light at once. This makes it more suitable for small-scale production of customized clinical devices.³¹

4.4. Thermal Processing and Laser Ablation

Micro-injection moulding is used for high-volume production of thermoplastic MNs, such as those made from polycarbonate. Molten polymer is injected into a cooled micro-mould under high pressure, allowing for rapid cycle times. Laser ablation, using high-power femtosecond or nanosecond lasers, is employed to cut microneedle shapes directly from thin metal or polymer sheets. This method is highly versatile and does not require expensive masks or molds.³²

5. Mechanism of Microneedle transdermal drug delivery

Phase-1- Physical Penetration - Application of microneedle patch on the skin

Phase-2 – Microchannel formation- Microneedle penetrate into stratum corneum by fracturing the lipid bilayer in the skin

Phase-3 – Transdermal transport - Drug enters into stratum corneum and diffuses through viable epidermis. This increases the drug permeability

Phase-4– Systemic Pharmacokinetics- Drug enters into the blood stream at the target site with no hepatic first pass effect

Phase-5 – Skin recovery - Microchannels naturally close within some time and stratum corneum restores within 72 hours with no permanent damage to the skin.³²

6. ADVANCED CHARACTERIZATION OF MICRONEEDLE SYSTEMS

Rigorous characterization is mandatory to ensure the safety and performance of Microneedle systems. Evaluation focuses on mechanical strength, morphology, and physicochemical stability.

6.1. Mechanical Characterization

The mechanical performance of Microneedles is the primary determinant of their ability to successfully penetrate the skin barrier without breaking.

Axial Compression Testing: A single needle or array is compressed against a hard surface using a texture analyser. The force-displacement curve is monitored to identify the failure point (buckling or fracture). For a 600 µm needle, a fracture force exceeding 0.5 N per needle is typically required to ensure penetration.^33,34

Insertion Force: Measured by pressing the Microneedle array against a skin mimic or excised skin. The force at which the first "pop" or drop in resistance occurs represents the insertion threshold. This value should be low (0.1 to 3 N for an array) to allow for manual application.³⁵

Safety Factor: Defined as the ratio of the fracture force to the insertion force. A safety factor of at least 5 is recommended for clinical applications to prevent needle breakage during handling or misapplication.³⁶

6.2. Morphological and Dimensional Evaluation

The geometry of Microneedles including height, base width, and tip radius critically affects the drug delivery rate and the level of pain.

Scanning Electron Microscopy (SEM): SEM provides detailed images of the needle surface, allowing researchers to verify tip sharpness and the fidelity of the fabrication process. It is used to identify defects such as rounded tips, shaft cracks, or surface roughness.³⁷

Confocal Laser Scanning Microscopy (CLSM): CLSM allows for the non-invasive visualization of the Microneedles in the skin. By labelling the drug with a fluorescent dye, researchers can map the three-dimensional distribution and penetration depth (typically 100 to 350 µm) of the drug within the epidermis.³⁸

Optical Microscopy: Research microscopes (e.g., Olympus SZX16) equipped with digital cameras allow for rapid screening and quantitative measurements of array dimensions.³⁹

6.3. PHYSICOCHEMICAL STABILITY AND DRUG LOADING

Drug Content Uniformity: Assessed by dissolving Microneedle patches in a suitable solvent and analysing the solution via HPLC or UV-Vis spectrophotometry. High uniformity (±5%) is essential for consistent clinical dosing.⁴⁰

Weight Variation and Swelling: Patches are individually weighed to ensure batch-to-batch consistency. Swelling index testing for hydrogel Microneedles measures the capacity to absorb interstitial fluid, which directly correlates with the diffusion-based drug release rate.⁴¹

FTIR Spectroscopy: Used to identify potential chemical interactions (e.g., hydrogen bonding) between the drug and the polymer matrix by analysing shifts in characteristic absorption peaks.⁴²

Differential Scanning Calorimetry (DSC): Evaluates the thermal properties and physical state of the drug within the MNs. The disappearance of a drug’s crystalline melting peak suggests the formation of a stable amorphous dispersion, which can enhance solubility and release.⁴³

7. BIOLOGICAL EVALUATION AND PERMEATION METRICS

The transition from benchtop characterization to clinical validation requires rigorous testing in both in vitro and in vivo models to assess efficacy and safety.

7.1. IN VITRO DRUG RELEASE AND PERMEATION STUDIES

Franz diffusion cells are utilized to model the release of drugs from MNs into the body. This setup consists of a donor and a receptor compartment separated by a semi-permeable membrane. The MN patch is applied to a pre-conditioned dialysis membrane or excised skin (porcine or human). The receptor compartment is filled with phosphate-buffered saline (PBS) at pH 6.8 or 7.4, maintained at a physiological temperature of 32°C to 37°C. The receiver phase is stirred using a magnetic bead to maintain sink conditions. Samples are withdrawn at regular intervals (e.g., 0.5, 1, 2, 4, 8, 12, and 24 hours) and analysed for drug concentration via validated HPLC or UV-Vis methods. This allows researchers to calculate the cumulative drug release and determine the release kinetics (e.g., zero-order, first-order, or Higuchi model).^44,45

7.2. IN VIVO ANIMAL MODEL STUDIES: SAFETY AND EFFICACY

To validate the pharmacokinetic performance of microneedles, in vivo studies are conducted using animal models, most commonly hairless rats or pigs. These animals are chosen for their skin’s anatomical and physiological similarity to human skin.

Transepidermal Water Loss (TEWL): TEWL is monitored using a vapometer before and after MN application. An increase in TEWL indicates successful disruption of the stratum corneum barrier. Monitoring the return of TEWL to baseline (typically within 24–72 hours) allows for the assessment of skin recovery kinetics.⁴⁶

Histological Evaluation: Skin biopsies are taken post-treatment, stained with Hematoxylin and Eosin (H&E), and examined under a microscope. This confirms the depth of needle penetration and ensures that no permanent tissue damage or significant inflammatory response has occurred.

Pharmacokinetic (PK) Analysis: Serial blood samples are collected and analysed via HPLC or LC-MS/MS. Key parameters include the time to reach maximum concentration (T_max), the peak concentration (C_max), and the area under the curve (AUC), which reflects the total systemic exposure. These PK profiles are compared with traditional injections to evaluate the relative efficiency of MN delivery.⁴⁷

8. THERAPEUTIC APPLICATIONS AND FUTURE PERSPECTIVES

Microneedles have moved beyond conceptual frameworks to significant clinical applications in numerous therapeutic areas.

8.1. Vaccination and Global Health

The skin is rich in antigen-presenting cells (APCs), such as Langerhans cells. Delivering vaccines via MNs targets these cells directly, often resulting in a more robust immune response compared to traditional intramuscular injections. This "dose-sparing" effect allows for the use of smaller amounts of antigen to achieve protective immunity. Furthermore, the stability of vaccines in solid-state MN patches eliminates the need for a cold chain, significantly reducing the cost and logistical challenges of mass vaccination campaigns in developing countries.⁴⁸

8.2. Chronic Disease Management and Hormonal Therapy

For patients with chronic conditions requiring daily injections, such as diabetes (insulin) or growth hormone deficiencies, Microneedles offer a painless and patient-friendly alternative. Sustained-release Hydrogel Microneedles are particularly promising for maintaining steady hormone levels over several days or weeks. Integration with biosensors could lead to closed-loop systems that monitor biomarkers and deliver drugs accordingly.⁴⁹

8.3. Oncology and Targeted Therapy

Microneedles are being investigated for the local delivery of chemotherapeutic agents directly into tumor sites, particularly for skin cancers like melanoma. This approach maximizes the local drug concentration while minimizing systemic toxicity. Furthermore, MNs can deliver immunotherapeutic agents to modulate the tumor microenvironment.^50,51

8.4. Dermatology and Cosmetics

In the cosmetic industry, MN patches are used to deliver anti-aging compounds (e.g., hyaluronic acid, peptides) and treatments for skin disorders like alopecia and hyperpigmentation. MNs also show potential in scar management by delivering drugs directly into the fibrotic tissue. ^52,53,54

8.5. Challenges in Clinical Translation and Regulatory Hurdles

Despite their potential, several hurdles remain for the widespread adoption of microneedles. Moving from laboratory-scale micro moulding to high-throughput industrial manufacturing requires standardized processes and robust quality control. As combination products (device + drug), microneedles must satisfy both medical device and pharmaceutical regulations, requiring extensive safety and stability data. Sterilization methods must be validated to ensure they do not degrade the drug or the polymer matrix.

9. CONCLUSION

Microneedle technology stands at the forefront of the next generation of drug delivery systems. By merging the benefits of needle-based and needle-free delivery, it provides a minimally invasive, efficient, and patient-compliant platform for a vast range of therapeutics. Continued advancements in microfabrication, polymer science, and biosensing will likely address current limitations in drug loading and scalability, paving the way for microneedles to become a standard of care in global vaccination campaigns and chronic disease management. The transition from purely physical penetration to intelligent, responsive delivery systems marks the beginning of a new era in personalized medicine.

REFERENCES

1. Gorzelanny C, Mess C, Schneider SW, Huck V, Brandner JM. Skin Barriers in Dermal Drug Delivery: Which Barriers Have to Be Overcome and How Can We Measure Them? Pharmaceutics. 2020 Jul 20;12(7):684.
2. Jepps OG, Dancik Y, Anissimov YG, Roberts MS. Modeling the human skin barrier — Towards a better understanding of dermal absorption. Advanced Drug Delivery Reviews. 2013 Feb;65(2):152–68.
3. Zhao L, Chen J, Bai B, Song G, Zhang J, Yu H, et al. Topical drug delivery strategies for enhancing drug effectiveness by skin barriers, drug delivery systems and individualized dosing. Frontiers in Pharmacology. 2024 Jan 16;14.
4. Queiroz MLB, Shanmugam S, Santos LNS, Campos C de A, Santos AM, Batista MS, et al. Microneedles as an alternative technology for transdermal drug delivery systems: a patent review. Expert Opinion on Therapeutic Patents. 2020 Apr 12;30(6):433–52.
5. Van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. Journal of Controlled Release. 2012 Jul;161(2):645–55.
6. Hou X, Li J, Hong Y, Ruan H, Long M, Feng N, et al. Advances and Prospects for Hydrogel-Forming Microneedles in Transdermal Drug Delivery. Biomedicines. 2023 Aug 1;11(8):2119.
7. Joshi N, Sina Azizi Machekposhti, Narayan RJ. Evolution of transdermal drug delivery devices and novel microneedle technologies: A historical perspective and review. JID Innovations. 2023 Nov 1;3(6):100225–5.
8. De Decker I, Logé T, Hoeksema H, Speeckaert MM, Blondeel P, Monstrey S, et al. Dissolving microneedles for effective and painless intradermal drug delivery in various skin conditions: A systematic review. The Journal of Dermatology. 2023 Jan 26;50(4):422–44.
9. Kováčik A, Kopečná M, Vávrová K. Permeation enhancers in transdermal drug delivery: benefits and limitations. Expert Opinion on Drug Delivery. 2020 Jan 14;17(2):145–55.
10. Mo R, Zhang H, Xu Y, Wu X, Wang S, Zheng D, et al. Transdermal drug delivery via microneedles to mediate wound microenvironment. Advanced Drug Delivery Reviews. 2023 Apr 1; 195:114753–3.
11. Filho D, Guerrero M, Pariguana M, Marican A, Durán-Lara EF. Hydrogel-Based Microneedle as a Drug Delivery System. Pharmaceutics. 2023 Oct 10;15(10):2444–4.
12. Lotfollahi Z. The anatomy, physiology and function of all skin layers and the impact of ageing on the skin. Wound Practice & Research. 2024 Mar 1;32(1):6–10.
13. Lefèvre-Utile A, Braun C, Haftek M, Aubin F. Five Functional Aspects of the Epidermal Barrier. International Journal of Molecular Sciences. 2021 Oct 28;22(21):11676.
14. Quan T. Molecular insights of human skin epidermal and dermal aging. Journal of Dermatological Science. 2023 Nov 1;112(2):48–53.
15. Mostafavi Yazdi SJ, Baqersad J. Mechanical modeling and characterization of human skin: A review. Journal of Biomechanics. 2022 Jan 1; 130:110864.
16. Liu M, Lu F, Feng J. Aging and homeostasis of the hypodermis in the age-related deterioration of skin function. Cell Death & Disease. 2024 Jun 24;15(6):1–11.
17. Norlén L, Lundborg M, Wennberg C, Narangifard A, Daneholt B. The Skin’s Barrier: A Cryo-EM Based Overview of its Architecture and Stepwise Formation. Journal of Investigative Dermatology. 2021 Aug 31;142(2):285–92.
18. Alkilani A, McCrudden MT, Donnelly R. Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the Stratum Corneum. Pharmaceutics. 2015 Oct 22;7(4):438–70.
19. Haj-Ahmad R, Khan H, Arshad M, Rasekh M, Hussain A, Walsh S, et al. Microneedle Coating Techniques for Transdermal Drug Delivery. Pharmaceutics. 2015 Nov 5;7(4):486–502.
20. Nagarkar R, Singh M, Nguyen HX, Jonnalagadda S. A review of recent advances in microneedle technology for transdermal drug delivery. Journal of Drug Delivery Science and Technology. 2020 Oct; 59:101923.
21. Qu F, Geng R, Liu Y, Zhu J. Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment. Theranostics. 2022;12(7):3372–406.
22. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin’s barrier function. Pharmaceutical Science & Technology Today. 2000 Sep;3(9):318–26.
23. Waghule T, Singhvi G, Dubey SK, Pandey MM, Gupta G, Singh M, et al. Microneedles: a Smart Approach and Increasing Potential for Transdermal Drug Delivery System. Biomedicine & Pharmacotherapy. 2019 Jan; 109:1249–58.
24. Arora M, Laskar TT. Microneedles: Recent advances and development in the field of transdermal drug delivery technology. Journal of Drug Delivery and Therapeutics. 2023 Mar 15;13(3):155–63.
25. Courtenay AJ, McCrudden MTC, McAvoy KJ, McCarthy HO, Donnelly RF. Microneedle-Mediated Transdermal Delivery of Bevacizumab. Molecular Pharmaceutics. 2018 Jul 11;15(8):3545–56.
26. Ahmed KS, Shan X, Mao J, Qiu L, Chen J. Derma roller microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect. Materials Science and Engineering: C. 2019 Jun; 99:1448–58.
27. Benbrook N, Zhan W. Mathematical modelling of hollow microneedle-mediated transdermal drug delivery. Drug Delivery and Translational Research. 2025 Feb 6.
28. Panda A, Matadh VA, Suresh S, Shivakumar HN, Murthy SN. Non-dermal applications of microneedle drug delivery systems. Drug Delivery and Translational Research. 2021 Feb 24.
29. Jung JH, Jin SG. Microneedle for transdermal drug delivery: current trends and fabrication. Journal of Pharmaceutical Investigation. 2021 Mar 4;51.
30. Du G, he P, Zhao J, He C, Jiang M, Zhang Z, et al. Polymeric microneedle-mediated transdermal delivery of melittin for rheumatoid arthritis treatment. Journal of Controlled Release. 2021 Aug; 336:537–48.
31. Ruan S, Zhang Y, Feng N. Microneedle-mediated transdermal nanodelivery systems: a review. Biomaterials Science. 2021;9(24):8065–89.
32. Zhu DD, Zhang XP, Zhang BL, Hao YY, Guo XD. Safety Assessment of Microneedle Technology for Transdermal Drug Delivery: A Review. Advanced Therapeutics. 2020 Jun 8;3(8):2000033.
33. Mbituyimana B, Bukatuka CF, Qi F, Ma G, Shi Z, Yang G. Microneedle-mediated drug delivery for scar prevention and treatment. Drug Discovery Today. 2023 Nov;28(11):103801.
34. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Advanced Drug Delivery Reviews. 2012 Nov;64(14):1547–68.
35. He H, Wang Z, Kadireya Aikelamu, Bai J, Shen Q, Gao X, et al. Preparation and In Vitro Characterization of Microneedles Containing Inclusion Complexes Loaded with Progesterone. Pharmaceutics. 2023 Jun 19;15(6):1765–5.
36. Deshpande A, Mer V, Patel D, Thakkar H. Microneedle-assisted transdermal delivery of carvedilol nanosuspension for the treatment of hypertension. RSC Pharmaceutics. 2024 Jan 1.
37. Harieth Alrimawi B, Lee JY, Ng KW, Goh CF. In vitro evaluation of microneedle strength: a comparison of test configurations and experimental insights. RSC Pharmaceutics. 2024;1(2):227–33.
38. Visscher M, Frijlink HW, Hinrichs WLJ. What Is the Optimal Geometry of Dissolving Microneedle Arrays? A Literature Review. Pharmaceutics. 2025 Jan 17;17(1):124.
39. Wang Y, Ma G, Gao G, Tao J, Cao W, Sun H, et al. Bioimaging of Dissolvable Microneedle Arrays: Challenges and Opportunities. Research. 2022 Aug 1; 2022:1–23.
40. Aldawood FK, Andar A, Desai S. A Comprehensive Review of Microneedles: Types, Materials, Processes, Characterizations and Applications. Polymers. 2021 Aug 22;13(16):2815.
41. Faraji Rad Z, Prewett PD, Davies GJ. High-resolution two-photon polymerization: the most versatile technique for the fabrication of microneedle arrays. Microsystems & Nanoengineering. 2021 Sep 3;7(1).
42. Hu X, Liu J, Wang Q, Hu Q, Sun H, Wang S, et al. Colon cancer-cell-specific drug delivery by gemcitabine conjugated with peptide chain targeting ENO1. International Journal of Pharmaceutics. 2025 Mar 1; 673:125402–2.
43. Elkhashab M, Sartawi Z, Faisal W, Crean A. Glassy Drug Microneedle Array Design: Drug Glass-Forming Ability and Stability. Molecular Pharmaceutics. 2025 Feb 17.
44. Wang Y, Huo Y, Zhao C, Liu H, Shao Y, Zhu C, et al. Engineered exosomes with enhanced stability and delivery efficiency for glioblastoma therapy. Journal of Controlled Release. 2024 Apr 1; 368:170–83.
45. Derel HG. Method Development and Validation of in Vitro Release Test for Fluorometholone Ophthalmic Suspension using Franz Diffusion Cell System. Global Journal of Pharmacy & Pharmaceutical Sciences. 2021 Nov 18;9(2).
46. Sharma R, Yadav S, Yadav V, Akhtar J, Katari O, Kuche K, et al. Recent advances in lipid-based long-acting injectable depot formulations. Advanced Drug Delivery Reviews. 2023 Aug 1; 199:114901.
47. Olatunji O, Das DB. Drug Delivery Using Microneedles. Elsevier eBooks. 2015 Jan 1.
48. Enhancement of Skin Permeability with Microneedles Techniques: From Conceptual Framework to Commercial Products - A Comprehensive Review. Letters in Applied NanoBioScience. 2024 Dec 30;13(4):155.
49. Jamin NR, Astuti NT, Pratiwi PD. Cellophane Membranes In In Vitro Permeation Studies Using Franz Diffusion Cells: A Review. JURNAL FARMASIMED (JFM). 2026 Apr 30;8(2):876–84.
50. Mishra NK, Agarwal S, Raghava GP. Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacology. 2010 Jul 16;10(1).
51. Shestovskaya MV, Luss AL, Безбородова ОА, Makarov VV, Keskinov AA. Iron Oxide Nanoparticles in Cancer Treatment: Cell Responses and the Potency to Improve Radiosensitivity. Pharmaceutics. 2023 Sep 30;15(10):2406–6.
52. Waghule T, Singhvi G, Dubey SK, Pandey MM, Gupta G, Singh M, et al. Microneedles: a Smart Approach and Increasing Potential for Transdermal Drug Delivery System. Biomedicine & Pharmacotherapy. 2019 Jan; 109:1249–58.
53. Derel HG. Method Development and Validation of in Vitro Release Test for Fluorometholone Ophthalmic Suspension using Franz Diffusion Cell System. Global Journal of Pharmacy & Pharmaceutical Sciences. 2021 Nov 18;9(2).
54. Harieth Alrimawi B, Lee JY, Ng KW, Goh CF. In vitro evaluation of microneedle strength: a comparison of test configurations and experimental insights. RSC Pharmaceutics. 2024;1(2):227.